FDA CONFIRMS SEASTAR MEDICAL HAS FULFILLED THE POST-APPROVAL STUDY REQUIREMENTS FOR QUELIMMUNE® FOR THE TREATMENT OF SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY (AKI) IN PEDIATRIC PATIENTS

Reuters · 4d ago

Please log in to view news